1-6 of 6
Josyf C. Mychaleckyj
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy

Jan Skupien, Adam M. Smiles, Erkka Valo, Tarunveer S. Ahluwalia, Beata Gyorgy, Niina Sandholm, Stephanie Croall, Maria Lajer, Kevin McDonnell, Carol Forsblom, Valma Harjutsalo, Michel Marre, Andrzej T. Galecki, David-Alexandre Tregouet, Chun Yi Wu, Josyf C. Mychaleckyj, Helen Nickerson, Marlon Pragnell, Stephen S. Rich, Marcus G. Pezzolesi, Samy Hadjadj, Peter Rossing, Per-Henrik Groop, Andrzej S. Krolewski
Journal: Diabetes Care
Diabetes Care 2019;42(1):93–101
https://doi.org/10.2337/dc18-1369
Published: 19 November 2018
View article titled, Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy
Open the PDF for Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy in another window
Journal Articles

Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial

Mario Luca Morieri, He Gao, Marie Pigeyre, Hetal S. Shah, Jennifer Sjaarda, Christine Mendonca, Timothy Hastings, Patinut Buranasupkajorn, Alison A. Motsinger-Reif, Daniel M. Rotroff, Ronald J. Sigal, Santica M. Marcovina, Peter Kraft, John B. Buse, Michael J. Wagner, Hertzel C. Gerstein, Josyf C. Mychaleckyj, Guillaume Parè, Alessandro Doria
Journal: Diabetes Care
Diabetes Care 2018;41(11):2404–2413
https://doi.org/10.2337/dc18-0709
Published: 27 September 2018
View article titled, Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial
Open the PDF for Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD

Hetal S. Shah, Mario Luca Morieri, Santica M. Marcovina, Ronald J. Sigal, Hertzel C. Gerstein, Michael J. Wagner, Alison A. Motsinger-Reif, John B. Buse, Peter Kraft, Josyf C. Mychaleckyj, Alessandro Doria
Journal: Diabetes Care
Diabetes Care 2018;41(2):348–355
https://doi.org/10.2337/dc17-1638
Published: 28 November 2017
View article titled, Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD
Open the PDF for Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD in another window
Includes: Supplementary data
Journal Articles

Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial

Hetal S. Shah, He Gao, Mario Luca Morieri, Jan Skupien, Skylar Marvel, Guillaume Paré, Gaia C. Mannino, Patinut Buranasupkajorn, Christine Mendonca, Timothy Hastings, Santica M. Marcovina, Ronald J. Sigal, Hertzel C. Gerstein, Michael J. Wagner, Alison A. Motsinger-Reif, John B. Buse, Peter Kraft, Josyf C. Mychaleckyj, Alessandro Doria
Journal: Diabetes Care
Diabetes Care 2016;39(11):1915–1924
https://doi.org/10.2337/dc16-0285
Published: 15 August 2016
View article titled, Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial
Open the PDF for Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Synergism Between Circulating Tumor Necrosis Factor Receptor 2 and HbA1c in Determining Renal Decline During 5–18 Years of Follow-up in Patients With Type 1 Diabetes and Proteinuria

Jan Skupien, James H. Warram, Monika A. Niewczas, Tomohito Gohda, Maciej Malecki, Josyf C. Mychaleckyj, Andrzej T. Galecki, Andrzej S. Krolewski
Journal: Diabetes Care
Diabetes Care 2014;37(9):2601–2608
https://doi.org/10.2337/dc13-1983
Published: 07 August 2014
View article titled, Synergism Between Circulating Tumor Necrosis Factor Receptor 2 and HbA<sub>1c</sub> in Determining Renal Decline During 5–18 Years of Follow-up in Patients With Type 1 Diabetes and Proteinuria
Open the PDF for Synergism Between Circulating Tumor Necrosis Factor Receptor 2 and HbA<sub>1c</sub> in Determining Renal Decline During 5–18 Years of Follow-up in Patients With Type 1 Diabetes and Proteinuria in another window
Includes: Supplementary data
Journal Articles

Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants

Josyf C. Mychaleckyj, DPHIL, Timothy Craven, MS, Uma Nayak, PHD, John Buse, MD, John R. Crouse, MD, Marshall Elam, MD, Kent Kirchner, MD, Daniel Lorber, MD, Santica Marcovina, PHD, William Sivitz, MD, JoAnn Sperl-Hillen, MD, Denise E. Bonds, MD, Henry N. Ginsberg, MD
Journal: Diabetes Care
Diabetes Care 2012;35(5):1008–1014
https://doi.org/10.2337/dc11-1811
Published: 11 April 2012
View article titled, Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
Open the PDF for Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants in another window
Includes: Supplementary data